Evrópusambandið - enska - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - acarbose - oral tablet - 50mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - acarbose - oral tablet - 100mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - acarbose - oral tablet - 100mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - acarbose - oral tablet - 50mg

Malta - enska - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 gram(s) - antibacterials for systemic use

Malta - enska - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 gram(s) - antibacterials for systemic use

Írland - enska - HPRA (Health Products Regulatory Authority)

ever valinject gmbh - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - pemetrexed

Evrópusambandið - enska - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

somex pharma - glimepiride - oral tablet - 1mg